Aurinia Pharmaceuticals Inc

Stock Chart, Company Information, and Scan Results

$12.21(as of Aug 26, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Aurinia Pharmaceuticals Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$12.21
Ticker SymbolAUPH
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees130
CountyUSA
Market Cap$1,597.3M

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc In Our Stock Scanner

As of Aug 27, 2025
As of ---
As of ---
As of ---
As of ---
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.